Building up its rare obesity pipeline, Rhythm Pharma to raise $150M
With fresh data in-hand for a slew of late-stage clinical trials in rare obesity diseases, Rhythm Pharma $RYTM signaled plans today to raise $150 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
